ArticleBritish journal of clinical pharmacology2016
Predicting allopurinol response in patients with gout.
Article in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 2020 American College of Rheumatology Guideline for the Management of Gout.Arthritis care & research · 2020Guideline
- Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.Clinical and translational science · 2021Trial
- Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.Clinical and translational science · 2020Trial
- A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.European journal of clinical pharmacology · 2017Trial
- A Pharmacometric Workflow for Resolving Model Instability in Model Use-Reuse Settings.CPT: pharmacometrics & systems pharmacology · 2025Article
- Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation.Acta pharmacologica Sinica · 2025Article
- Article
- Article
- Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.British journal of clinical pharmacology · 2023Article
- The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.Clinical and translational science · 2023Article
- Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom.The Lancet regional health. Europe · 2022Article
- Dose banding - Weighing up benefits, risks and therapeutic failure.British journal of clinical pharmacology · 2022Article
- Dosage individualization proposed for anti-gout medications among the patients with gout.PloS one · 2021Article
- Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia.Frontiers in pharmacology · 2021Article
- Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes.British journal of clinical pharmacology · 2019Article
- Gout, flares, and allopurinol use: a population-based study.Arthritis research & therapy · 2019Article
- Article
- Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.Current rheumatology reports · 2018Review
- Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.Arthritis research & therapy · 2018Article
- The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.British journal of clinical pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of ≤0.36 mmol l(-1) .
methodsA population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated.
resultsThe urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements.
conclusionsContrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.